MX2019008482A - Tratamiento medico que comprende administracion enteral de edaravona. - Google Patents
Tratamiento medico que comprende administracion enteral de edaravona.Info
- Publication number
- MX2019008482A MX2019008482A MX2019008482A MX2019008482A MX2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A MX 2019008482 A MX2019008482 A MX 2019008482A
- Authority
- MX
- Mexico
- Prior art keywords
- edaravone
- composition
- liquid
- enteral administration
- pharmaceutical composition
- Prior art date
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title abstract 8
- 229950009041 edaravone Drugs 0.000 title abstract 6
- 239000007788 liquid Substances 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008247 solid mixture Substances 0.000 abstract 2
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a una composición farmacéutica sólida dispersable en agua para su uso en el tratamiento de una enfermedad, comprendiendo dicho tratamiento la dispersión de la composición farmacéutica en un líquido acuoso para producir un líquido administrable por vía enteral que contiene al menos 0,5 gramos de composición farmacéutica y al menos 0,3 g/l de edaravona, seguido de la administración enteral de un líquido administrable por vía enteral a un paciente humano en una cantidad que proporciona una dosis de 30-300 mg de edaravona, comprendiendo dicha composición farmacéutica: un 2-50 % en peso de 3-metil-1-fenil-2-pirazolin-5-ona (edaravona); y un 3-50 % en peso de un agente alcalinizante soluble. Esta composición sólida que contiene edaravona se puede dispersar de forma sencilla en un líquido acuoso para preparar una solución acuosa de edaravona que se puede ingerir por parte del paciente. La composición sólida de la presente invención ofrece la ventaja de que edaravona se disuelve muy rápidamente cuando se introduce la composición en agua y de que el líquido administrable por vía enteral obtenido de este modo tiene elevada biodisponibilidad oral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17151741 | 2017-01-17 | ||
| PCT/EP2017/067005 WO2018133957A1 (en) | 2017-01-17 | 2017-07-06 | Medical treatment comprising enteral administration of edaravone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019008482A true MX2019008482A (es) | 2019-11-11 |
| MX390101B MX390101B (es) | 2025-03-20 |
Family
ID=57850912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008482A MX390101B (es) | 2017-01-17 | 2017-07-06 | Tratamiento medico que comprende administracion enteral de edaravona |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10966960B2 (es) |
| EP (1) | EP3570819B1 (es) |
| JP (1) | JP6898027B2 (es) |
| AU (1) | AU2017394478B2 (es) |
| BR (1) | BR112019014712A2 (es) |
| CA (1) | CA3050031A1 (es) |
| DK (1) | DK3570819T3 (es) |
| ES (1) | ES2868955T3 (es) |
| MX (1) | MX390101B (es) |
| PL (1) | PL3570819T3 (es) |
| PT (1) | PT3570819T (es) |
| WO (1) | WO2018133957A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050031A1 (en) | 2017-01-17 | 2018-07-26 | Treeway Tw001 B.V. | Medical treatment comprising enteral administration of edaravone |
| CN110996944A (zh) | 2017-07-06 | 2020-04-10 | 萃微Tw001公司 | 依达拉奉在口服治疗氧化应激介导的神经退行性疾病中的用途 |
| US11826352B2 (en) | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
| IL282773B2 (en) | 2018-11-02 | 2025-08-01 | Mitsubishi Tanabe Pharma Corp | Edaravone suspension for oral administration |
| WO2024172852A1 (en) | 2023-02-16 | 2024-08-22 | Slayback Pharma Llc | Stable pharmaceutical compositions of edaravone |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3758164B2 (ja) | 2000-10-24 | 2006-03-22 | 三菱ウェルファーマ株式会社 | 筋萎縮性側索硬化症（ａｌｓ）治療剤 |
| IS7278A (is) | 2001-11-26 | 2003-05-27 | Merlyn Associates, Inc. | Barkaslanga með stefnustjórnanlegum enda og stöðuhaldandi búnaði |
| CN1241565C (zh) | 2003-04-16 | 2006-02-15 | 浙江震元制药有限公司 | 依达拉奉药物组合物及制备 |
| CN100358520C (zh) | 2003-09-11 | 2008-01-02 | 彭建华 | 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法 |
| US20080161378A1 (en) | 2004-02-09 | 2008-07-03 | Hiide Yoshino | Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) or Diseases Caused by Als |
| CN101953832B (zh) | 2010-08-10 | 2012-02-15 | 南京师范大学 | β-环糊精包合依达拉奉的口服药物组合物及其制备方法 |
| CN102349893A (zh) * | 2011-08-19 | 2012-02-15 | 福建天泉药业股份有限公司 | 依达拉奉药物组合物 |
| US20140228420A1 (en) | 2011-09-05 | 2014-08-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof |
| CN103251554A (zh) | 2013-06-06 | 2013-08-21 | 南京亿华药业有限公司 | 一种稳定的依达拉奉注射液及其制备方法 |
| CN105816423B (zh) | 2016-03-16 | 2018-07-20 | 福建天泰医药科技有限公司 | 依达拉奉剂型 |
| CA3050031A1 (en) | 2017-01-17 | 2018-07-26 | Treeway Tw001 B.V. | Medical treatment comprising enteral administration of edaravone |
| KR102550376B1 (ko) | 2017-01-17 | 2023-07-04 | 트리웨이 티더블유001 비.브이. | 에다라본의 경구 또는 위 투여를 포함하는 치료 |
| CN110996944A (zh) | 2017-07-06 | 2020-04-10 | 萃微Tw001公司 | 依达拉奉在口服治疗氧化应激介导的神经退行性疾病中的用途 |
-
2017
- 2017-07-06 CA CA3050031A patent/CA3050031A1/en active Pending
- 2017-07-06 EP EP17737775.1A patent/EP3570819B1/en active Active
- 2017-07-06 PL PL17737775T patent/PL3570819T3/pl unknown
- 2017-07-06 ES ES17737775T patent/ES2868955T3/es active Active
- 2017-07-06 AU AU2017394478A patent/AU2017394478B2/en active Active
- 2017-07-06 PT PT177377751T patent/PT3570819T/pt unknown
- 2017-07-06 WO PCT/EP2017/067005 patent/WO2018133957A1/en not_active Ceased
- 2017-07-06 MX MX2019008482A patent/MX390101B/es unknown
- 2017-07-06 DK DK17737775.1T patent/DK3570819T3/da active
- 2017-07-06 BR BR112019014712-8A patent/BR112019014712A2/pt not_active Application Discontinuation
- 2017-07-06 JP JP2019559159A patent/JP6898027B2/ja active Active
-
2019
- 2019-07-12 US US16/510,497 patent/US10966960B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017394478A1 (en) | 2019-08-01 |
| CA3050031A1 (en) | 2018-07-26 |
| JP6898027B2 (ja) | 2021-07-07 |
| AU2017394478B2 (en) | 2023-07-20 |
| ES2868955T3 (es) | 2021-10-22 |
| PL3570819T3 (pl) | 2021-10-25 |
| WO2018133957A1 (en) | 2018-07-26 |
| US20190328711A1 (en) | 2019-10-31 |
| EP3570819A1 (en) | 2019-11-27 |
| JP2020506958A (ja) | 2020-03-05 |
| EP3570819B1 (en) | 2021-03-03 |
| PT3570819T (pt) | 2021-04-20 |
| MX390101B (es) | 2025-03-20 |
| BR112019014712A2 (pt) | 2020-02-18 |
| US10966960B2 (en) | 2021-04-06 |
| DK3570819T3 (da) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008482A (es) | Tratamiento medico que comprende administracion enteral de edaravona. | |
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| ES2834985T3 (es) | Composición que contiene cineol para administración nasal | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| GB2477590A (en) | A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| BR112021021904A2 (pt) | Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível | |
| HRP20121072T1 (hr) | Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX392901B (es) | Tratamiento que comprende la administracion oral o gastrica de edaravona | |
| BRPI0915119B8 (pt) | uso de iota carragenano | |
| JP2017105861A5 (es) | ||
| MX2019014675A (es) | Solucion de levodopa para infusion. | |
| Maskin et al. | Inhaled colistimethate sodium in ventilator-associated tracheobronchitis due to multidrug-resistant Gram-negative bacteria | |
| ES2643167T3 (es) | Procedimiento de producción y uso de un copolímero de carboximetilcelulosa sódica y gosipol | |
| CL2013002829A1 (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. | |
| Maldonado et al. | Update on Emerging Infections: news from the Centers for Disease Control and Prevention. Update to the CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections | |
| CN105451749B (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 | |
| AR111313A1 (es) | Composición osmóticamente activa para diálisis | |
| Bhadra et al. | Role of oral misoprostol for treatment of incomplete abortion |